SRPT

SRPT

USD

Sarepta Therapeutics Inc. Common Stock (DE)

$16.200+0.890 (5.813%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$15.310

最高价

$17.750

最低价

$15.080

成交量

2.09M

公司基本面

市值

1.7B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

7.10M

交易所

NMS

货币

USD

52周价格范围

最低价 $10.42当前价 $16.200最高价 $138.81

相关新闻

Analyst Upgrades

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.

查看更多
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Analyst Upgrades

Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15

Baird analyst Brian Skorney maintains Sarepta Therapeutics with a Neutral and lowers the price target from $21 to $15.

查看更多
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

查看更多
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Reuters

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.

查看更多
Sarepta slumps as gene therapy setback adds to drug pipeline woes
BusinessWire

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary

查看更多
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Analyst Upgrades

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $16

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics with a Neutral and raises the price target from $15 to $16.

BusinessWire

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025.